Woodline Partners »

Sab Biotherapeutics shares owned by Woodline Partners

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Woodline Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $5.7M 2.9M 2.01

More positions owned by Woodline Partners

Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Amazon (AMZN)
At&t (T)
Chubb (CB)
Eli Lilly & Co. (LLY)
Meta Platforms Cl A (META)
Keysight Technologies (KEYS)
Broadcom (AVGO)
Johnson & Johnson (JNJ)
Tesla Motors (TSLA)
Alphabet Cap Stk Cl A (GOOGL)
Merus N V (MRUS)
Autodesk (ADSK)

View all positions for Woodline Partners

Top funds holding Sab Biotherapeutics

Vivo Capital
RA Capital Management
Commodore Capital
Woodline Partners
Sessa Capital IM
BVF
Sphera Funds Management
Vanguard Group
HB Wealth Management
AWM Investment Company
Geode Capital Management
Renaissance Technologies
Pathstone Holdings
Virtu Financial
Kovitz Investment Group Partners

View all funds holding Sab Biotherapeutics